HansBiomed Corporation (KOSDAQ:042520)

Market Cap	412.87B +345.9%
Revenue (ttm)	100.17B +24.2%
Net Income	-27.44B
EPS	-2,097.10
Shares Out	14.26M
PE Ratio	n/a
Forward PE	22.21
Dividend	n/a
Ex-Dividend Date	n/a

Volume	415,825
Average Volume	342,598
Open	27,900
Previous Close	27,050
Day's Range	26,300 - 29,150
52-Week Range	6,970 - 57,800
Beta	n/a
RSI	48.95
Earnings Date	May 22, 2026

About HansBiomed

HansBiomed Corporation, together with its subsidiaries, engages in the research and development, production, and sale of medical materials for the procedure and the raw materials for medical supplies. The company provides ExFuse, a demineralized bone matrix with cancellous bone gel/putty; BellaFuse, a demineralized bone matrix; Genesis, a cancellous sponge block/filler; Pedi-Stick, a demineralized cortical bone stick; SureChip, a cancellous bone chip; OsteoGrow, a demineralized bone matrix inserter; BellaCell HD, an allograft dermal product tha...

• Founded: 1990
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 042520

Financial Performance

In fiscal year 2025, HansBiomed's revenue was 89.78 billion, an increase of 10.65% compared to the previous year's 81.14 billion. Losses were -31.34 billion, 333.9% more than in 2024.